Brokerages expect Evolent Health (NYSE:EVH) to announce earnings per share (EPS) of ($0.04) for the current fiscal quarter, according to Zacks Investment Research. Nine analysts have provided estimates for Evolent Health’s earnings. The lowest EPS estimate is ($0.07) and the highest is ($0.02). Evolent Health posted earnings per share of ($0.14) in the same quarter last year, which would suggest a positive year-over-year growth rate of 71.4%. The company is scheduled to announce its next quarterly earnings report on Tuesday, May 8th.
According to Zacks, analysts expect that Evolent Health will report full-year earnings of ($0.08) per share for the current financial year, with EPS estimates ranging from ($0.23) to $0.07. For the next year, analysts forecast that the firm will post earnings of $0.15 per share, with EPS estimates ranging from ($0.07) to $0.30. Zacks’ earnings per share averages are an average based on a survey of research analysts that follow Evolent Health.
Evolent Health (NYSE:EVH) last issued its quarterly earnings data on Tuesday, February 27th. The technology company reported ($0.10) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.10). Evolent Health had a negative return on equity of 3.51% and a negative net margin of 14.05%. The business had revenue of $113.97 million during the quarter, compared to analyst estimates of $111.09 million.
EVH has been the subject of a number of recent analyst reports. Citigroup initiated coverage on Evolent Health in a report on Thursday, January 4th. They issued a “buy” rating for the company. ValuEngine downgraded Evolent Health from a “sell” rating to a “strong sell” rating in a research report on Monday, April 2nd. Canaccord Genuity cut their target price on Evolent Health from $27.00 to $24.00 and set a “buy” rating for the company in a research report on Wednesday, February 28th. Zacks Investment Research downgraded Evolent Health from a “hold” rating to a “sell” rating in a research report on Thursday, March 8th. Finally, Wells Fargo cut their target price on Evolent Health from $27.00 to $20.00 and set an “outperform” rating for the company in a research report on Wednesday, February 28th. Three analysts have rated the stock with a sell rating and twelve have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $25.33.
In other Evolent Health news, Director Unitedhealth Group Inc sold 3,040,000 shares of the company’s stock in a transaction that occurred on Thursday, March 1st. The stock was sold at an average price of $13.70, for a total value of $41,648,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 8.79% of the company’s stock.
Several large investors have recently made changes to their positions in EVH. Nationwide Fund Advisors lifted its position in shares of Evolent Health by 14.1% during the 3rd quarter. Nationwide Fund Advisors now owns 105,375 shares of the technology company’s stock valued at $1,876,000 after acquiring an additional 13,057 shares during the last quarter. Rhumbline Advisers lifted its position in shares of Evolent Health by 18.1% during the 3rd quarter. Rhumbline Advisers now owns 54,474 shares of the technology company’s stock valued at $970,000 after acquiring an additional 8,351 shares during the last quarter. Bank of New York Mellon Corp lifted its position in shares of Evolent Health by 155.5% during the 3rd quarter. Bank of New York Mellon Corp now owns 565,410 shares of the technology company’s stock valued at $10,065,000 after acquiring an additional 344,113 shares during the last quarter. SG Americas Securities LLC acquired a new stake in shares of Evolent Health during the 3rd quarter valued at $156,000. Finally, American International Group Inc. lifted its position in shares of Evolent Health by 45.9% during the 3rd quarter. American International Group Inc. now owns 34,931 shares of the technology company’s stock valued at $622,000 after acquiring an additional 10,995 shares during the last quarter.
EVH stock traded down $0.35 on Monday, reaching $14.65. The company’s stock had a trading volume of 779,280 shares, compared to its average volume of 894,927. Evolent Health has a 52 week low of $10.30 and a 52 week high of $27.50. The firm has a market capitalization of $1,161.56, a price-to-earnings ratio of -20.93 and a beta of 1.07. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.85 and a quick ratio of 2.85.
WARNING: “Evolent Health (EVH) Expected to Post Earnings of -$0.04 Per Share” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/04/09/evolent-health-evh-expected-to-post-earnings-of-0-04-per-share.html.
About Evolent Health
Evolent Health, Inc, through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates as a managed services firm that supports health systems and physician organizations in migration toward value-based care and population health management.
Get a free copy of the Zacks research report on Evolent Health (EVH)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.